title: Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity.
abstract: This commentary provides the authors' perspective on the article "Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial," which has recently been published in The Lancet Oncology.
authors.affiliation: Laboratory of Tumor Immunology and Biology; National Cancer Institute; Bethesda, MD USA.
authors.forename: Ravi A
authors.initials: RA
authors.lastname: Madan
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Heery
authors.forename: James L
authors.initials: JL
authors.lastname: Gulley